Novo Capital Markets Day Set for Monday September 21 in London; First Under CEO Mike Doustdar and Under the New 'Novo' Operating Brand
Novo (formerly Novo Nordisk; NYSE: NVO; Copenhagen: NOVO-B) confirmed the Capital Markets Day will be held Monday September 21, 2026 in London, webcast live starting 09:00 BST / 10:00 CEST. The event is the first Capital Markets Day under CEO Mike Doustdar and the first outing under the rebranded 'Novo' identity introduced Monday September 14 with the tagline 'Lasting health starts now' and 'The Novo Way' culture framework. Sell-side previews (TIKR, Bloomberg, Kontra Invest) frame the event as a critical reset opportunity following the Friday September 11 Morgan Stanley Underweight downgrade (DKK 250 target), Barclays trim to DKK 300, and HSBC target raise to DKK 320 (Hold). Novo shares trade approximately 32% below the January 2026 52-week high of EUR 54.86. Priorities investors want addressed: the semaglutide 2031 loss of exclusivity, U.S. Wegovy pill script momentum (surpassing 5 million total prescriptions by August), CagriSema's late-2026 U.S. obesity decision path, the ziltivekimab HERMES + ATHENA heart-failure terminations, and how Wednesday's Anthropic Claude Science R&D collaboration and Thursday's $1.4 billion Orbis Medicines macrocycle deal fit the reset narrative.